Drug Trial Radar · NCT05505955
Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Oct 8, 2022
Primary completion
Nov 3, 2023
Study completion Nov 3, 2023
Sponsor
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function. The study was divided into three parts: Part 1: single ascending dose, randomized, double-blind study,with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions; Part 2: Multiple ascending dose, randomized, double-blind study,with 4 dose groups preset; Part 3: an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function.
Conditions
- Glomerulonephritis
Interventions
HRS-5965Drug
Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
PlaceboDrug
Subjects took Placebo in Part 1 and Part 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events to assess safety and tolerabilityTime frame: up to 24 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated hospital of QingDao University
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.